Published in Heart Disease Weekly, January 19th, 2003
Abiomed gained worldwide attention in 2001 by implanting 6 of its AbioCor hearts into critically ill patients. But surgeons have tried the procedure just once in 2002, and not at all since ending a moratorium on recruiting 3 months ago.
The slowdown of the trial has dispirited investors. Abiomed shares, which traded at $17 in December 2001, fell below $4 in December 2002.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.